Neovascular age-related macular degeneration (NAMD) wet AMD
Clinical trials for Neovascular age-related macular degeneration (NAMD) wet AMD explained in plain language.
Never miss a new study
Get alerted when new Neovascular age-related macular degeneration (NAMD) wet AMD trials appear
Sign up with your email to follow new studies for Neovascular age-related macular degeneration (NAMD) wet AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a single gene injection replace monthly eye shots for wet AMD?
Disease control Recruiting nowThis phase II trial is testing whether a single subretinal injection of JWK001, a gene therapy, can safely and effectively treat wet age-related macular degeneration (nAMD). The study includes about 50 adults aged 50-85 with active disease who have responded to prior aflibercept …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Gene therapy shot aims to tame wet AMD in both eyes
Disease control Recruiting nowThis study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD
Phase 2 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC